Change in 21-gene recurrence score (RS) (Oncotype DX) after exposure to neoadjuvant endocrine therapy.

被引：0
|
作者：
Hilal, Talal
Mi, Lanyu
Anderson, Karen S.
Pockaj, Barbara A.
Gray, Richard J.
Dixon, Leslie E.
Martinez, Erika D.
Singh, Charanjit
Northfelt, Donald W.
机构：
[1] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Phoenix, AZ USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Arizona State Univ, Temple, TX USA
[4] Mayo Clin Arizona, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e12650
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12650
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay)
    Hou, Yanjun
    Tozbikian, Gary
    Zynger, Debra L.
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (06) : 541 - 548
  • [22] Associations between the 21-gene Oncotype DX Recurrence Score (RS), Ki67, and Race in Early Breast Cancer (EBC) Using the National Cancer Database (NCDB)
    Patel, Rima
    Kwon, Deukwoo
    Van Hyfte, Grace
    Sparano, Joseph
    Tiersten, Amy
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Clinical application of the 21-gene oncotype recurrence score in an older cohort: A single center experience
    Chiru, E. D.
    Kuhar, C. Grasic
    Oseledchyk, A.
    Schotzau, A.
    Gonzalez, M. J.
    Kurzeder, C.
    Vetter, M.
    TRANSLATIONAL ONCOLOGY, 2023, 36
  • [24] Appropriate use of the 21-gene recurrence score (RS) assay across Michigan
    Ali, H. Y.
    Munir, K.
    Braun, T.
    Griggs, J. J.
    Silver, S. M.
    Gorski, D. H.
    Breslin, T. M.
    Henry, N. L.
    CANCER RESEARCH, 2016, 76
  • [25] The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer
    Jaime A. Pardo
    Betty Fan
    Alessandra Mele
    Stephanie Serres
    Monica G. Valero
    Isha Emhoff
    Amulya Alapati
    Ted A. James
    Annals of Surgical Oncology, 2021, 28 : 1320 - 1325
  • [26] Role of Oncotype DX® recurrence score in predicting nodal response after neoadjuvant chemotherapy in breast cancer
    Mele, Alessandra
    Alapati, Amulya
    James, Ted
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 172 - 172
  • [27] Is Low Tumor Grade an Exclusion Criterion for the 21-Gene Recurrence Score (RS) Assay?
    Gage, Michele
    Rosman, Martin
    Mylander, Charles
    Giblin, Erica
    Tafra, Lorraine
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 52 - 52
  • [28] Practice-changing use of 21-gene oncotype DX breast recurrence score assay in a public hospital in Brazil: Results of 155 cases.
    Mattar, Andre
    Fonseca, Guilherme Ribeiro
    Agudo Romao, Murilo Barato
    Shida, Jorge Yoshinori
    Agata Stiepcich, Monica Maria
    Jakubowski, Debbie M.
    Chao, Calvin Y.
    Oliveira, Sergio C.
    Gebrim, Luiz Henrique
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
    Dowsett, Mitch
    Sestak, Ivana
    Lopez-Knowles, Elena
    Sidhu, Kalvinder
    Dunbier, Anita K.
    Cowens, J. Wayne
    Ferree, Sean
    Storhoff, James
    Schaper, Carl
    Cuzick, Jack
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (22) : 2783 - +
  • [30] The Role of Oncotype DX(R) Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer
    Pardo, Jaime A.
    Fan, Betty
    Mele, Alessandra
    Serres, Stephanie
    Valero, Monica G.
    Emhoff, Isha
    Alapati, Amulya
    James, Ted A.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (03) : 1320 - 1325
12345